3-吗啉-4-基-1-丁胺 | 776329-10-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 恶嗪烷类
• 中文名称: 3-吗啉-4-基-1-丁胺
• 中文别名: 3-(4-吗啉基)-1-丁胺
• 英文名称: 3-morpholin-4-yl-butylamine
• 英文别名: 3-Morpholin-4-ylbutan-1-amine
• CAS: 776329-10-3
• 化学式: C₈H₁₈N₂O
• 分子量: 158.244
• InChiKey: PJRDKXUODLOYBV-UHFFFAOYSA-N

物化性质

• 沸点：
  239.1±25.0 °C(Predicted)
• 密度：
  0.983±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -0.3
• 重原子数：
  11
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  38.5
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 危险等级：
  IRRITANT
• 海关编码：
  2934999090

反应信息

• 作为反应物：
  描述：

  1,5-二氯-2,4-二硝基苯 、 3-吗啉-4-基-1-丁胺 生成 5-chloro-2,4-dinitro-N-(3-morpholin-4-yl-butyl)-aniline
  参考文献：
  名称：

  Winkelmann; Raether; Dittmar, Arzneimittel-Forschung/Drug Research, 1975, vol. 25, # 5, p. 681 - 708

  摘要：

  DOI：
• 作为产物：
  描述：

  吗啉 、 3-丁烯-1-胺 在 silver tetrafluoroborate 、 chloro(1,5-cyclooctadiene)rhodium(I) dimer 、 1,3-双(二苯基膦)丙烷 作用下， 以 乙二醇二甲醚 为溶剂， 反应 48.0h， 生成 4-(吗啉-4-基)-1-丁胺 、 3-吗啉-4-基-1-丁胺
  参考文献：
  名称：

  Anti-Markovnikov Hydroamination of Homoallylic Amines

  摘要：

  The development of an anti-Markovnikov-selective hydroamination of unactivated alkenes is a significant challenge in organometallic chemistry. Herein, we present the rhodium-catalyzed anti-Markovnikov-selective hydroamination of homoallylic amines. The proximal Lewis basic amine serves to promote reactivity and enforce regioselectivity through the formation of the favored metallacycle, thus over-riding the inherent reactivity of the alkene. The scope of both the amine nudeophiles and homoallylic amines that participate in the reaction is demonstrated.

  DOI：

  10.1021/jacs.5b08500

文献信息

• Novel pyridazinone derivatives as pharmaceuticals and pharmaceutical compositions containing them
  申请人：Holder Swen

  公开号：US20050026918A1

  公开（公告）日：2005-02-03

  The present invention relates to novel pyridazinone derivatives of the general formula (I) wherein A is A1 or A2; R is unsubstituted or at least monosubstituted C 1 -C 10 -alkyl, aryl, aryl-(C 1 -C 10 -alkyl)-, heteroaryl, heteroaryl-(C 1 -C 10 -alkyl)-, heterocyclyl, heterocyclyl-(C 1 -C 10 -alkyl)-, C 3 -C 10 -cycloalkyl, polycycloalkyl, C 2 -C 10 -alkenyl or C 2 -C 10 -alkinyl and Ar is unsubstituted or at least monosubstituted aryl or heteroaryl.

  本发明涉及一种新型吡啶并咪唑酮衍生物，其通式为(I)，其中A为A1或A2；R为未取代或至少单取代的C1-C10烷基、芳基、芳基-(C1-C10烷基)-、杂芳基、杂芳基-(C1-C10烷基)-、杂环基、杂环基-(C1-C10烷基)-、C3-C10环烷基、多环环烷基、C2-C10烯基或C2-C10炔基，Ar为未取代或至少单取代的芳基或杂芳基。
• Imino ether derivative compounds and drugs containing the compounds as the active ingredient
  申请人：Ishida Akiharu

  公开号：US20070167490A1

  公开（公告）日：2007-07-19

  The compound represented by formula (I) (wherein R 1 and R 2 are cyclic group which may have a substituent(s) and so on; W is a spacer of which main chain has an atom number of 1-6.; X is —O— and so on; ring A is cyclic group which may have a substituent(s); Y is a spacer of which main chain has an atom number of 1-6 and so on; Z is acidic group.) a salt thereof, a solvent thereof or an N-oxide thereof, or a prodrug thereof Since the compounds in the present invention have a regulatory activity for peroxisome proliferator activated receptor, the compounds in the present invention are useful as a preventive and/or therapeutic agent for diseases associating metabolic disorders (e.g., hypercholesterolemia, hyperlipoproteinemia, etc.), hyperlipidemia, atherosclerosis, hypertension, circulatory diseases, overeating, ischemic heart diseases, etc., an HDL cholesterol-elevating agent, an LDL cholesterol and/or a VLDL cholesterol-lowering agent and a drug for relief from risk factors of diabetes or metabolic syndrom.

  化合物的化学式为（I）（其中R1和R2是环状基团，可以具有取代基等；W是具有1-6个原子数的主链的间隔物；X是-O-等；环A是环状基团，可以具有取代基等；Y是具有1-6个原子数的主链的间隔物等；Z是酸性基团）其盐、溶剂或N-氧化物，或其前药。由于本发明中的化合物具有对过氧化物酶体增殖物激活受体的调节活性，因此本发明中的化合物可用作预防和/或治疗代谢紊乱（如高胆固醇血症、高脂蛋白血症等）、高脂血症、动脉硬化、高血压、循环系统疾病、暴饮暴食、缺血性心脏病等的药物，以及一种升高HDL胆固醇的药物，降低LDL胆固醇和/或VLDL胆固醇的药物，以及缓解糖尿病或代谢综合征风险因素的药物。
• IMINO ETHER DERIVATIVE COMPOUNDS AND DRUGS CONTAINING THE COMPOUNDS AS THE ACTIVE INGREDIENT
  申请人：ONO PHARMACEUTICAL CO., LTD.

  公开号：EP1602642A1

  公开（公告）日：2005-12-07

  The compound represented by formula (I) (wherein R1 and R2 are cyclic group which may have a substituent(s) and so on.; W is a spacer of which main chain has an atom number of 1-6.; X is -O- and so on.; ringA is cyclic group which may have a substituent(s).; Y is a spacer of which main chain has an atom number of 1-6 and so on.; Z is acidic group.) a salt thereof, a solvent thereof or an N-oxide thereof or a prodrug thereof Since the compounds in the present invention have a regulatory activity for peroxisome proliferator activated receptor, the compounds in the present invention are useful as a preventive and/or therapeutic agent for diseases associating metabolic disorders (e.g., hypercholesterolemia, hyperlipoproteinemia, etc.), hyperlipidemia, atherosclerosis, hypertension, circulatory diseases, overeating, ischemic heart diseases, etc., an HDL cholesterol-elevating agent, an LDL cholesterol and/or a VLDL cholesterol-lowering agent and a drug for relief from risk factors of diabetes or metabolic syndrom.

  式(I)代表的化合物 (其中 R1 和 R2 为环状基团，可带有取代基等；W 为间隔基，其主链的原子序数为 1-6；X 为-O-等；ringA 为环状基团，可带有取代基等；Y 为间隔基，其主链的原子序数为 1-6；Z 为酸性基团)。)的盐、其溶剂或其 N-氧化物或其原药 由于本发明中的化合物具有过氧化物酶体增殖物活化受体的调节活性，因此本发明中的化合物可用作与代谢紊乱有关的疾病（如高胆固醇血症、高血脂症、高血压、高血糖、高血脂症等）的预防和/或治疗剂、高胆固醇血症、高脂蛋白血症等）、高血脂症、动脉粥样硬化、高血压、循环系统疾病、暴饮暴食、缺血性心脏病等相关疾病的预防和/或治疗剂、高密度脂蛋白胆固醇升高剂、低密度脂蛋白胆固醇和/或低密度脂蛋白胆固醇降低剂以及缓解糖尿病或代谢综合征危险因素的药物。
• PYRIDAZINONE DERIVATIVES AS GSK-3BETA INHIBITORS
  申请人：Sanofi-Aventis Deutschland GmbH

  公开号：EP1581505B1

  公开（公告）日：2007-08-01
• PYRIDAZINONE DERIVATIVES AS CDK2-INHIBITORS
  申请人：Aventis Pharma S.A.

  公开号：EP1611121B1

  公开（公告）日：2007-08-08